Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of CKD-381 vs D026 in Healthy Subjects
NCT03558425Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-381 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the plasma drug concentration-time curve within a dosing interval at steady state and Percent decrease from baseline in integrated gastric acidity. Started Jun 2018; status: completed.
02
Drugs
CKD-381
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03558425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558425.